RxDoctor Payments DataLook up a doctor →

Mohammad Qasaymeh, MD

Neurology with Special Qualifications in Child Neurology · Amherst, NYNPI 1528074341

Payments from drug & device makers

$462,694in general payments, 2019–2025

Across 787 payments — averaging $587.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurology Practice Consortium GPO, LLC$420K
  • Biohaven Pharmaceuticals, Inc.$21K
  • AbbVie$6K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • Livanova USA, Inc.$3K
  • UCB, Inc.$2K
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$1,1853%
  • Speaking & faculty fees$23,00054%
  • Travel & lodging$2,9507%
  • Food & beverage$15,12436%
  • Education$1540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurology Practice Consortium GPO, LLC7$420,282
Biohaven Pharmaceuticals, Inc.57$21,282
AbbVie(2 entities)116$5,992
Biohaven Pharmaceutical Holding Company Ltd.22$2,810
Livanova USA, Inc.65$2,534
UCB, Inc.88$1,896
SK Life Science, Inc.24$793
Teva Pharmaceuticals USA, Inc.39$761
Pfizer42$734
Jazz Pharmaceuticals Inc.21$576
Neurelis, Inc.36$465
Greenwich Biosciences, Inc.21$377
Amgen19$326
GE HealthCare46$323
Biogen14$313
AstraZeneca(2 entities)11$310
Catalyst Pharmaceuticals, Inc.10$224
Supernus Pharmaceuticals, Inc.12$211
Corium, LLC10$207
Sunovion Pharmaceuticals Inc.15$189
Lilly USA, LLC9$166
Acadia Pharmaceuticals Inc7$148
Amneal Pharmaceuticals LLC8$141
Eisai Inc.7$113
Pyros Pharmaceuticals, Inc.1$112
Impel Pharmaceuticals LLC5$108
Azurity Pharmaceuticals, Inc.5$101
PTC Therapeutics, Inc.6$90
Takeda Pharmaceuticals U.S.A., Inc.6$84
Harmony Biosciences LLC3$82
Upsher-smith Laboratories LLC6$82
Springworks Therapeutics, Inc.3$64
Neurocrine Biosciences, Inc.4$61
Neos Therapeutics, LP3$56
Assertio Therapeutics, Inc.4$55
Avanir Pharmaceuticals, Inc.2$48
Zogenix Inc.2$36
Johnson & Johnson(2 entities)2$36
Merz North America, Inc.1$34
Ironshore Pharmaceuticals Inc.2$33
Biocodex, Inc.2$33
Aquestive Therapeutics, Inc.2$30
Lundbeck LLC2$30
Alnylam Pharmaceuticals Inc.2$26
Sumitomo Pharma America, Inc.2$24
Grifols USA, LLC1$23
Octapharma USA, Inc.1$22
Scilex Pharmaceuticals Inc.1$21
Novartis1$21
Impel Pharmaceuticals Inc.1$19
Zyla Life Sciences, Inc.1$19
Xeris Pharmaceuticals, Inc.1$19
Ipsen Biopharmaceuticals, Inc1$19
Vanda Pharmaceuticals Inc.1$19
Axsome Therapeutics, Inc.1$17
Merck1$17
Otsuka America Pharmaceutical, Inc.1$17
Tanabe Pharma America, Inc.1$16
CSL Behring1$15
Avion Pharmaceuticals1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$462,694 in reported general payments places this provider in the 95th percentile of 161 neurology with special qualifications in child neurology providers in New York.

See all neurology with special qualifications in child neurology providers in New York →

Medicare billing

Part B allowed, 2024
$6,294
Medicare patients
18
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Amherst

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →